Paul Dietze

is of counsel with Haynes Boone. He has more than 15 years of experience practicing intellectual property law in pharmaceutical, chemical, and biotechnology arts. Prior to becoming a patent attorney, Dr. Dietze was a chemistry professor who taught a variety of graduate and undergraduate chemistry courses and supervised a funded research group. He also spent more than four years at the United States Food and Drug Administration as a review chemist in the Division of Oncologic Drug Products. Additionally, Dr. Dietze was a Postdoctoral Research Fellow in the Brandeis University Graduate Department of Biochemistry from August 1984 to September 1987. He is the author of more than 15 publications in peer reviewed scientific journals.

Recent Articles by Paul Dietze

Acorda Therapeutics v. Mylan Pharmaceuticals May Not be the Last Word on Personal Jurisdiction in ANDA Cases

The Federal Circuit held that Mylan Pharmaceuticals, Inc. (“Mylan”), a generic drug manufacturer, was subject to specific personal jurisdiction in Delaware because Mylan had filed an abbreviated new drug application (“ANDA”) and “contemplate[d] plans to engage in marketing of the proposed generic drugs” in the state.[1] The ruling affirmed two different decisions by judges in the United States District Court for the District of Delaware that Mylan was subject to specific jurisdiction in Delaware.[2] However, as noted below, it looks like Mylan intends to seek panel or en banc rehearing and possibly pursue a petition for certiorari if the Federal Circuit does not grant the rehearing or re-hears the case and continues to find personal jurisdiction.

May 2, 2016

View All Posts